PhytoMedical, Ricerca to develop muscle-wasting treatment

By Elaine Rigoli

Tampa, Fla., July 10 - PhytoMedical Technologies, Inc. said the company will advance from "pre-clinical to clinical" when Ricerca BioSciences, as part of a new development agreement, begins work on PhytoMedical's BDC-03 compound for cachexia, a muscle-wasting condition that afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients.

In fact, PhytoMedical said half of all cancer-related deaths are a result of cachexia, not the cancer itself.

BDC-03 has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

Ricerca's responsibilities will eventually expand to include PhytoMedical's other compounds.

Ricerca is a drug development company located in Concord, Ohio.

PhytoMedical is an early stage research-based biopharmaceutical company based in Princeton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.